Syed Ibad Hussain

Syed Ibad Hussain

Auto-generated profile, based on publicly available information

Syed Ibad Hussain

Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2025 in Future Oncology
Verified
Journal Article
Closed access
AJAmna Amir Jalal
Amna Amir Jalal
ZAZain Ul Abideen
Zain Ul Abideen
ESErum Siddiqui
Erum Siddiqui
SDShaikh Muhammad Daniyal
Shaikh Muhammad Daniyal
AAArsalan Ahmed
Arsalan Ahmed
MSMuhammad Salih
Muhammad Salih
This systematic review and meta-analysis compared the diagnostic performance and complication profiles of transperineal biopsy (TPBx) versus transrectal biopsy (TRBx) for prostate cancer, incorporating recent randomized and large observational studies. Following PRISMA 2020 guidelines, PubMed, Scopus, Embase, and Cochrane Library were searched till April 2025. Studies directly comparing TPBx and TRBx were included. Risk of bias was assessed using RoB 2.0 for randomized trials and the Newcastle - Ottawa Scale for observational studies. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses and a GRADE assessment were performed to evaluate the certainty of evidence. Twenty-nine studies (n = 90,621) were included. TPBx showed higher PCa detection (RR 1.08; 95% CI 1.01-1.15; p = 0.02) and csPCa detection (RR 1.14; 95% CI 1.05-1.24; p = 0.001), though the certainty of evidence was low to moderate. Heterogeneity was moderate to high. TPBx also showed lower infection-related complications and comparable overall events, though procedure-related pain was slightly higher. TPBx offers improved diagnostic yield and lower infection risk compared with TRBx, with comparable safety. However, given the moderate heterogeneity and limited high-quality RCTs, further confirmatory trials are necessary. https://www.crd.york.ac.uk/PROSPERO identifier is CRD420251035763.

1 December 2025 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
AJAmna Amir Jalal
Amna Amir Jalal
SHSyed Ibad Hussain
Syed Ibad Hussain
MKMuhammad Saad Khan
Muhammad Saad Khan
ESErum Siddiqui
Erum Siddiqui
HCHarshika Khaim Chandani
Harshika Khaim Chandani
SSShanza Shakir
Shanza Shakir
Objective: To assess the efficacy and safety of pitolisant, a selective histamine H₃ receptor antagonist/inverse agonist, for excessive daytime sleepiness (EDS) in narcolepsy or obstructive sleep apnea (OSA). Data Sources: PubMed, Cochrane, Embase, Scopus, and Web of Science were searched through August 2025 for randomized placebo-controlled trials (RCTs). Study Selection and Data Extraction: Eligible RCTs reported Epworth Sleepiness Scale (ESS) or Pediatric Daytime Sleepiness Scale (PDSS), mean sleep latency, EQ-5D, or global impression outcomes. Two reviewers independently screened studies, extracted data, and assessed bias using Cochrane RoB 2.0. Publication bias was evaluated using funnel plots and Egger’s test; certainty of evidence was rated with GRADE. Data Synthesis: Six RCTs ( n = 1149) met the inclusion criteria. Compared with placebo, pitolisant significantly reduced Sleepiness Scale scores (SSS) (mean difference [MD] = −2.97; 95% confidence interval [CI] −3.62 to −2.33), increased mean sleep latency (MD = 3.06; 95% CI 2.12-3.99), and improved EQ-5D scores (MD = 2.68; P = 0.009). Patient global opinion (risk ratio [RR] = 1.40) and clinical global impression of change (CGI-C) (RR = 1.41) also favored pitolisant. Rates of treatment-emergent adverse events, serious adverse events, and withdrawals were comparable with placebo, and common adverse effects, such as headache, insomnia, nausea, and anxiety, were infrequent and not significantly increased. Relevance to Patient Care and Clinical Practice: Pitolisant provides an effective, nonstimulant option for EDS in narcolepsy and OSA, including residual symptoms despite continuous positive airway pressure (CPAP). Its distinct mechanism and tolerability profile make it a valuable alternative or adjunct to existing therapies, supporting personalized care and enhanced daily functioning. Conclusion and Relevance: Pitolisant significantly improves subjective and objective wakefulness and quality of life in EDS due to narcolepsy or OSA, with robust evidence for ESS benefit and a favorable safety profile.

16 March 2026 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
AJAmna Amir Jalal
Amna Amir Jalal
SHSyed Ibad Hussain
Syed Ibad Hussain
ESErum Siddiqui
Erum Siddiqui
MKMuhammad Saad Khan
Muhammad Saad Khan
MBMuhammad Burhan
Muhammad Burhan
MAMahrukh Amir
Mahrukh Amir
Injectable PCSK9 inhibitors effectively lower LDL-C levels in patients with hypercholesterolemia; however, their high cost and requirement for parenteral administration limit their widespread use. Oral PCSK9 inhibitors have emerged as a convenient alternative. This review and meta-analysis of the literature evaluate the effectiveness and safety of oral PCSK9 inhibitor treatment for adults with hypercholesterolemia. PubMed, Embase, Cochrane CENTRAL, and Scopus were searched through September 2025 for randomized controlled trials comparing oral PCSK9 inhibitors with placebo. The primary outcome was percentage change in LDL-C, with secondary lipid and safety outcomes. We used Cochrane RoB 2.0 tool to assess risk of bias, and pooled estimates were calculated using a random-effects model. Certainty of evidence was evaluated with GRADE. From 1253 records, 3 trials were included. Participants were mostly men, aged 61–65 years, with elevated baseline LDL-C. Oral PCSK9 inhibitors significantly reduced LDL-C and ApoB in a dose-dependent manner and achieved modest reductions in triglycerides (MD –6.56 mg/dL; 95% CI, −12.30 to −0.83) and total cholesterol (MD –25.25 mg/dL; 95% CI, −30.67 to −19.83). Effects on lipoprotein(a) were inconsistent. Adverse events (RR 1.06; 95% CI, 0.91–1.23) and serious adverse events (RR 1.32; 95% CI, 0.41–4.26) were comparable with placebo. According to our review, oral PCSK9 inhibitors are a promising therapeutic option for treating hypercholesterolemia because of their potent lipid-lowering effects and an overall favorable safety profile. However, more trials are needed to confirm their impact on cardiovascular outcomes.

13 August 2026 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
ZAZahabia Adnan
Zahabia Adnan
AJAmna Amir Jalal
Amna Amir Jalal
AHAbdullah Hameed
Abdullah Hameed
SASyed Hassan Ali
Syed Hassan Ali
SSShanza Shakir
Shanza Shakir
ARAhmed Asad Raza
Ahmed Asad Raza
Objective: To compare the efficacy and safety of levetiracetam versus sodium valproate as antiseizure therapy in children with new-onset epilepsy or established status epilepticus. Data Sources: PubMed, Cochrane Library, Embase, and Scopus were searched from inception to March 2026, without language restriction, using combinations of “epilepsy,” “status epilepticus,” “pediatric,” “levetiracetam,” and “sodium valproate,” with hand-searching of reference lists. Study Selection and Data Extraction: Randomized controlled trials and cohort studies of levetiracetam versus sodium valproate in children (≤18 years) were eligible. Two reviewers independently screened records, extracted data, and appraised quality (Cochrane RoB 2; Newcastle–Ottawa Scale for the cohort study). Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects Mantel-Haenszel model, with certainty graded by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Data Synthesis: Eight studies (7 randomized trials and 1 prospective cohort) were included. Levetiracetam and sodium valproate were comparably effective for seizure freedom (RR = 1.01; 95% CI = 0.93-1.10) and for failure to achieve seizure freedom (RR = 1.00; 95% CI = 0.73-1.36). Levetiracetam significantly reduced overall AEs (RR = 0.78; 95% CI = 0.68-0.89) and weight gain (RR = 0.22; 95% CI = 0.10-0.46), both high certainty. Behavioral changes (RR = 2.15; 95% CI = 0.81-5.70) and skin rash (RR = 1.01; 95% CI = 0.50-2.04) did not differ significantly. Relevance to Patient Care and Clinical Practice: This is among the first meta-analyses to pool pediatric data for these agents across both new-onset epilepsy and status epilepticus and to grade outcome certainty. The findings support levetiracetam as a preferred initial monotherapy when weight, tolerability, reproductive safety, or interaction risk is a priority, with behavioral monitoring during use. Conclusions: Levetiracetam and sodium valproate offer similar seizure control in pediatric epilepsy and status epilepticus, but levetiracetam has a more favorable safety profile, particularly for adverse effects and weight gain. High-quality pediatric trials with longer follow-up are needed to confirm the long-term efficacy.

9 April 2025 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
EAEisha Abid
Eisha Abid
AAAreeba Abid
Areeba Abid
HAHiba Abid
Hiba Abid
SHSyed Ibad Hussain
Syed Ibad Hussain
AJAmna Amir Jalal
Amna Amir Jalal